Aug 11, 2025 • Benzinga
SOMEWHAT-BULLISH
Veterinary Diagnostics Market is expected to generate a revenue of USD 4.52 Billion by 2031, Globally, at 6.59% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
Aug 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Why Qiagen ( QGEN ) International Revenue Trends Deserve Your Attention
Examine the evolution of Qiagen's (QGEN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Aug 08, 2025 • Benzinga
BULLISH
Baculovirus Expression System Market Poised for Significant Growth, Estimate to Hit USD 781.8 Million by 2032 | Coherent Market Insights
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.
Aug 07, 2025 • Benzinga
SOMEWHAT-BULLISH
DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - AppLovin ( NASDAQ:APP ) , Crocs ( NASDAQ:CROX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised Qiagen N.V. QGEN price target from $48 to $50. UBS analyst John Sourbeer maintained a Neutral ...
Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Qiagen ( QGEN ) Matches Q2 Earnings Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and +1.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 28, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
CERVOMED INC ( CRVO ) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.